Diagnosis and treatment of bacterial diarrhea

被引：7

作者：

James V. Lawler

Mark R. Wallace

机构：

[1] Infectious Diseases Department, National Naval Medical Center, Bethesda, MD 20889

来源：

Current Gastroenterology Reports | 2003年 / 5卷 / 4期

关键词：

Rifaximin; Stool Culture; Quinolone Resistance; Infectious Diarrhea; Diarrheal Illness;

D O I：

10.1007/s11894-003-0065-z

中图分类号：

学科分类号：

摘要：

Diarrheal illness caused by bacterial pathogens is a global health problem and remains one of the most common complaints prompting patients to seek medical care. Strategies to increase the yield of stool culture and new rapid diagnostic tests can improve diagnostic ability. Emerging antimicrobial resistance among the common bacterial causes of diarrhea has made treatment more challenging. Emerging fluoroquinolone resistance is a particular concern. Recent studies of rifaximin, a nonabsorbed antibiotic for the treatment of bacterial diarrhea, have shown favorable results. Rifaximin may represent a much-needed addition to the armamentarium against bacterial agents. Copyright © 2003 by Current Science Inc.

引用

页码：287 / 294

页数：7

共 59 条

[51]

Kuschner R.A., Trofa A.F., Thomas R.J., Et al., Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent, Clin. Infect. Dis., 21, pp. 536-541, (1995)

[52]

Akalin H.E., Quinolones in the treatment of acute bacterial diarrhoeal diseases, Drugs, 45, SUPPL. 3, pp. 114-118, (1993)

[53]

Pichler H., Diridl G., Wolf D., Ciprofloxacin in the treatment of acute bacterial diarrhea: A double blind study, Eur. J. Clin. Microbiol., 5, pp. 241-243, (1986)

[54]

Wistrom J., Jertborn M., Ekwall E., Et al., Empiric treatment of acute diarrheal disease with norfloxacin: A randomized, placebo-controlled study, Ann. Intern. Med., 117, pp. 202-208, (1992)

[55]

Ericsson C.D., Johnson P.C., DuPont H.L., Et al., Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea: A placebo-controlled, randomized trial, Ann. Intern. Med., 106, pp. 216-220, (1987)

[56]

Steffen R., Rifaximin: A nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea, J. Travel Med., 8, SUPPL. 2, (2001)

[57]

Ericsson C.D., Rifaximin: A new approach to the treatment of travelers' diarrhea: Conclusion, J. Travel Med., 8, SUPPL. 2, (2001)

[58]

DuPont H.L., Ericsson C.D., Mathewson J.J., Et al., Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers' diarrhea, Digestion, 59, pp. 708-714, (1998)

[59]

DuPont H.L., Jiang Z.D., Ericsson C.D., Et al., Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: A randomized, double-blind clinical trial, Clin. Infect. Dis., 33, pp. 1807-1815, (2001)

← 1 2 3 4 5 6 →